AA
Alexion, AstraZeneca Rare Disease (Boston, MA). 2024 revenue ~$7B. Soliris (eculizumab), Ultomiris (ravulizumab). Complement inhibitor pioneer. PNH, aHUS, gMG, NMOSD. Acquired by AstraZeneca (2021).
AA
Alexion AstraZeneca
@alexion
Joined July 2026
6 Following1 Followers